nach oben

Erschienen in:

2021 | OriginalPaper | Buchkapitel

35. Strahlentherapie: Methodenspezifische Komplikationen

verfasst von : Dirk Bottke

Erschienen in: Komplikationen in der Urologie

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Strahlentherapeutische Verfahren wie die perkutane Radiatio und die Low-dose-rate-(LDR-) oder High-dose-rate-(HDR-)Brachytherapie sind neben der radikalen Prostatektomie die einzigen kurativen Behandlungsoptionen beim Prostatakarzinom, an dem diese unter besonderer Berücksichtigung möglicher Komplikationen erläutert werden.

Ziel der Strahlentherapie ist es, eine möglichst hohe lokale Tumorkontrollrate zu erreichen und akute sowie späte Nebenwirkungen zu minimieren. Dazu muss das Zielvolumen mit einer ausreichend hohen homogen verteilten Dosis bestrahlt werden, die außerhalb des Zielvolumens möglichst steil abfällt, da ein Zusammenhang zwischen der Dosisbelastung der Risikoorgane (Harnblase, Urethra, Rektum, Sigma, Dünndarm, Penisbulbus, Hüftköpfe) und dem Auftreten von Begleitreaktionen besteht.

Bauman G, Rumble RB, Chen J, Loblaw A, Warde P, Members of the IMRT Indications Expert Panel (2012) Intensity-modulated radiotherapy in the treatment of prostate cancer. Clin On-col (R Coll Radiol) 24:461–473CrossRef

Becker-Schiebe M, Abaci A, Ahmad T, Hoffmann W (2016) Reducing radiation-associated toxicity using online image guidance (IGRT) in prostate cancer patients undergoing dose-escalated radiation therapy. Rep Pract Oncol Radiother 21:188–194PubMedPubMedCentralCrossRef

Bylund KC, Bayouth JE, Smith MC, Hass AC, Bhatia SK, Buatti JM (2008) Analysis of interfraction prostate motion using megavoltage cone beam computed tomography. Int J Radiat Oncol Biol Phys 72:949–956PubMedCrossRef

Challapalli A, Jones E, Harvey C, Hellawell GO, Mangar SA (2012) High dose rate prostate brachytherapy: an overview of the rationale, experience and emerging applications in the treatment of prostate cancer. Br J Radiol 85:S18–S27PubMedPubMedCentralCrossRef

Chasseray M, Dissaux G, Bourbonne V, Boussion N, Goasduff G, Malloreau J, Malhaire JP, Fournier G, Tissot V, Pradier O, Valeri A, Schick U (2019) Dose to the penile bulb and individual patient anatomy are predictive of erectile dysfunction in men treated with (125)I low dose rate brachytherapy for localized prostate cancer. Acta Oncol 58:1029–1035PubMedCrossRef

Chin J, Rumble RB, Kollmeier M, Heath E, Efstathiou J, Dorff T, Berman B, Feifer A, Jacques A, Loblaw DA (2017) Brachytherapy for patients with prostate cancer: American society of clinical oncology/cancer care ontario joint guideline update. J Clin Oncol 35:1737–1743PubMedCrossRef

Clarke RE, Tenorio LM, Hussey JR, Toklu AS, Cone DL, Hinojosa JG, Desai SP, Dominguez Parra L, Rodrigues SD, Long RJ, Walker MB (2008) Hyperbaric oxygen treatment of chronic refractory radiation proctitis: a randomized and controlled double-blind crossover trial with long-term follow-up. Int J Radiat Oncol Biol Phys 72:134–143PubMedCrossRef

Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341–1346PubMedCrossRef

DaSilva AF, Tuch DS, Wiegell MR, Hadjikhani N (2003) A primer on diffusion tensor imaging of anatomical substructures. Neurosurg Focus 15:E4PubMedCrossRef

Davis BJ, Taira AV, Nguyen PL, Assimos DG, D’Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, McLaughlin PW, Movsas B, Prestidge BR, Showalter TN, Vapiwala N (2016) ACR Appropriateness Criteria®. Permanent Source Brachytherapy for Prostate Cancer. [Reston, US-VA]: ACR [American College of Radiology]. https://acsearch.acr.org/docs/69399/Narrative/. Zugegriffen: 22. Jan. 2020

Donner CS (1998) Pathophysiology and therapy of chronic radiation-induced injury to the colon. Dig Dis 16:253–261PubMedCrossRef

Garg AK, Mai WY, McGary JE, Grant WH 3rd, Butler EB, Teh BS (2006) Radiation proctopathy in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 66:1294–1305PubMedCrossRef

Georgiou A, Grigsby PW, Perez CA (1993) Radiation induced lumbosacral plexopathy in gynecologic tumors: clinical findings and dosimetric analysis. Int J Radiat Oncol Biol Phys 26:479–482PubMedCrossRef

Goldner G, Pötter R, Kranz A, Bluhm A, Dörr W (2011) Healing of late endoscopic changes in the rectum between 12 and 65 months after external beam radiotherapy. Strahlenther Onkol 187:202–205PubMedCrossRef

Hauswald H, Kamrava MR, Fallon JM, Wang PC, Park SJ, Van T, Borja L, Steinberg ML, Demanes DJ (2016) High-dose-rate monotherapy for localized prostate cancer: 10-year results. Int J Radiat Oncol Biol Phys 94:667–674PubMedCrossRef

Henry A (2017) Permanent and high dose rate brachytherapy (Technique, Indications, Results, Morbidity). In: Bolla M, van Poppel H (Hrsg) Management of prostate cancer. Springer, Switzerland, S 187–202CrossRef

Herden J, Ansmann L, Ernstmann N, Schnell D, Weißbach L (2016) Therapie des lokal begrenzten Prostatakarzinoms im deutschen Versorgungsalltag. Dtsch Arztebl 113:329–336

Herden J, Ernstmann N, Schnell D, Weißbach L (2014) Die HAROW-Studie: ein Beispiel für Versorgungsforschung. Prospektive, nicht-interventionelle Studie zur Behandlung des Niedrig-Risiko-Prostatakarzinoms. Urologe 53:1743–1752CrossRef

Hoffman KE, Penson DF, Zhao Z, Huang LC, Conwill R, Laviana AA, Joyce DD, Luckenbaugh AN, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O’Neil BB, Kaplan SH, Greenfield S, Koyama T, Barocas DA (2020) Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA 323:149–163PubMedPubMedCentralCrossRef

Hoskin PJ, Motohashi K, Bownes P, Bryant L, Ostler P (2007) High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. Radiother Oncol 84:114–120PubMedCrossRef

Hoskin PJ, Rojas AM, Bownes PJ, Lowe GJ, Ostler PJ, Bryant L (2012) Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol 103:217–222PubMedCrossRef

Iglicki F, Coffin B, Ille O, Flourié B, Amarenco G, Lémann M, Messing B (1996) Fecal inconti-nence after pelvic radiotherapy: evidences for a lumbosacral plexopathy. Report of a case. Dis Colon Rectum 39:465–467PubMedCrossRef

Kaassis M, Oberti E, Burtin P, Boyer J (2000) Argon plasma coagulation for the treatment of hemorrhagic radiation proctitis. Endoscopy 32:673–776PubMedCrossRef

Kennedy M, Bruninga K, Mutlu EA, Losurdo J, Choudhary S, Keshavarzian A (2001) Successful and sustained treatment of chronic radiation proctitis with antioxidant vitamins E and C. Am J Gastroenterol 96:1080–1084PubMedCrossRef

Kochhar R, Sriram PV, Sharma SC, Goel RC, Patel F (1999) Natural history of late radiation proctosigmoiditis treated with topical sucralfate suspension. Dig Dis Sci 44:973–978PubMedCrossRef

Kranz J, Maurer G, Maurer U, Deserno O, Schulte S, Steffens J (2017) Harnröhrenstrikturrate nach Bestrahlung eines Prostatakarzinoms. Urologe 56:336–341CrossRef

Kushwaha RS, Hayne D, Vaizey CJ, Wrightham E, Payne H, Boulos PB (2003) Physiologic changes of the anorectum after pelvic radiotherapy for the treatment of prostate and blad-der cancer. Dis Colon Rectum 46:1182–1188PubMedCrossRef

Lanciano RM, Martz K, Montana GS, Hanks GE (1992) Influence of age, prior abdominal surgery, fraction size, and dose on complications after radiation therapy for squamous cell cancer of the uterine cervix. A Patterns Care Study Cancer 69:2124–2130PubMed

Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2019a) Interdisziplinäre Leitlinie der Qualität S. 3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 5.1, 2019a, AWMF Registernummer: 043/022OL. http://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/. Zugegriffen: 06 Jan. 2020

Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2019b) Supportive Therapie bei onkologischen PatientInnen – Langversion 1.2, 2019b, AWMF Registernummer: 032/054OL. http://leitlinienprogramm-onkologie.de/Supportive-Therapie.95.0.html. Zugegriffen: 28. Jan. 2020

Martinez AA, Demanes J, Vargas C, Schour L, Ghilezan M, Gustafson GS (2010) High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer. Am J Clin Oncol 33:481–488PubMedCrossRef

Merrell KW, Davis BJ, Goulet CC, Furutani KM, Mynderse LA, Harmsen WS, Wilson TM, McLaren RH, Deufel CL, Birckhead BJ, Funk RK, McMenomy BP, Stish BJ, Choo CR (2019) Reducing seed migration to near zero with stranded-seed implants: comparison of seed migration rates to the chest in 1000 permanent prostate brachytherapy patients undergoing implants with loose or stranded seeds. Brachytherapy 18:306–312PubMedCrossRef

Morris WJ, Tyldesley S, Rodda S, Halperin R, Pai H, McKenzie M, Duncan G, Morton G, Hamm J, Murray N (2017) Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 98:275–285PubMedCrossRef

Mottet N, van den Bergh RCN, Briers E, Cornford P, De Santis M, Fanti S, Gillessen S, Grummet J, Henry AM, Lam TB, Mason MD, van der Kwast TH, van der Poel HG, Rouvière O, Tilki D, Wiegel T (2019) Prostate Cancer [Full Guideline]. Arnhem, NL: EAU [European Association of Urology]. http://uroweb.org/guideline/prostate-cancer/. Zugegriffen: 22. Jan. 2020

National Cancer Institute (2017) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm

Perez CA, Brady LW (1993a) Acute Radiation Morbidity Scoring Criteria (RTOG). In: Perez CA, Brady LW (Hrsg) Principles and practice of radiation oncology, 2. Aufl. Lippincott, Philadelphia, S 51–53

Perez CA, Brady LW (1993b) Late Radiation Morbidity Scoring Criteria (RTOG, EORTC). In: Perez CA, Brady LW (Hrsg) Principles and practice of radiation oncology, 2. Aufl. Lippincott, Philadelphia, S 53–55

Petersen S, Jongen J, Petersen C, Sailer M (2007) Radiation-induced sequelae affecting the continence organ: incidence, pathogenesis, and treatment. Dis Colon Rectum 50:1466–1474PubMedCrossRef

Putta S, Andreyev HJ (2005) Faecal incontinence: a late side-effect of pelvic radiotherapy. Clin Oncol (R Coll Radiol) 17:469–477CrossRef

Roach M 3rd, Marquez C, Yuo HS, Narayan P, Coleman L, Nseyo UO, Navvab Z, Carroll PR (1994) Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 28:33–37PubMedCrossRef

Roach M 3rd, Nam J, Gagliardi G, El Naqa I, Deasy JO, Marks LB (2010) Radiation dose-volume effects and the penile bulb. Int J Radiat Oncol Biol Phys 76(3 Suppl):S130–S134PubMedPubMedCentralCrossRef

Rosenbaum CM, Engel O, Fisch M, Kluth LA (2017) Harnröhrenstrikturen nach Strahlentherapie. Urologe 56:306–312CrossRef

Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT (2008) Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358:1250–1261PubMedCrossRef

Sanguineti G, Franzone P, Marcenaro M, Foppiano F, Vitale V (2003) Sucralfate versus mesalazine versus hydrocortisone in the prevention of acute radiation proctitis during conformal radiotherapy for prostate carcinoma. A randomized study. Strahlenther Onkol 179:464–470PubMedCrossRef

Sasai T, Hiraishi H, Suzuki Y, Masuyama H, Ishida M, Terano A (1998) Treatment of chronic post-radiation proctitis with oral administration of sucralfate. Am J Gastroenterol 93:1593–1595PubMedCrossRef

Sathya JR, Davis IR, Julian JA, Guo Q, Daya D, Dayes IS, Lukka HR, Levine M (2005) Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 23:1192–1199PubMedCrossRef

Sherman DM, Mangini L, Poirier P, Kadish SP (1989) Double-blind comparison of loperamide and placebo in the treatment of radiation-induced diarrhea. Adv Ther 6:103–111

Sihono DSK, Ehmann M, Heitmann S, von Swietochowski S, Grimm M, Boda-Heggemann J, Lohr F, Wenz F, Wertz H (2018) Determination of intrafraction prostate motion during external beam radiation therapy with a transperineal 4-dimensional ultrasound real-time tracking system. Int J Radiat Oncol Biol Phys 101:136–143PubMedCrossRef

Smith DP, King MT, Egger S, Berry MP, Stricker PD, Cozzi P, Ward J, O’Connell DL, Armstrong BK (2009) Quality of life three years after diagnosis of localised prostate cancer: population based cohort study. BMJ 339:b4817PubMedPubMedCentralCrossRef

Stübinger SH, Wilhelm R, Kaufmann S, Döring M, Hautman S (2008) Brachytherapie des Prostatakarzinoms. Urologe 47:284–290CrossRef

Tagkalidis PP, Tjandra JJ (2001) Chronic radiation proctitis. ANZ J Surg 71:230–237PubMedCrossRef

Taïeb S, Rolachon A, Cenni JC, Nancey S, Bonvoisin S, Descos L, Fournet J, Gérard JP, Flourié B (2001) Effective use of argon plasma coagulation in the treatment of severe radiation proctitis. Dis Colon Rectum 44:1766–1771PubMedCrossRef

Taylor JG, Disario JA, Bjorkman DJ (2000) KTP laser therapy for bleeding from chronic radiation proctopathy. Gastrointest Endosc 52:353–357PubMedCrossRef

Theodorescu D, Gillenwater JY, Koutrouvelis PG (2000) Prostatourethral-rectal fistula after prostate brachytherapy. Cancer 89:2085–2091PubMedCrossRef

Tolkach Y, Kristiansen G (2017) Pathogenese urologischer Komplikationen nach Strahlentherapie. Urologe A 56:293–300PubMedCrossRef

Tran A, Wallner K, Merrick G, Seeberger J, Armstrong J, Mueller A, Cavanagh W, Lin D, Butler W (2005) Rectal fistulas after prostate brachytherapy. Int J Radiat Oncol Biol Phys 63:150–154PubMedCrossRef

Tsubokura T, Yamazaki H, Masui K, Sasaki N, Shimizu D, Suzuki G, Nakamura S, Yamada K, Okihara K, Shiraishi T, Yoshida K, Nishikawa T, Okabe H (2018) Comparison of image-guided intensity-modulated radiotherapy and low-dose rate brachytherapy with or without external beam radiotherapy in patients with localized prostate cancer. Sci Rep 8:10538PubMedPubMedCentralCrossRef

Valdagni R, Rancati T, Fiorino C (2009) Predictive models of toxicity with external radiotherapy for prostate cancer: clinical issues. Cancer 115(13 Suppl):3141–3149PubMedCrossRef

Vernia P, Fracasso PL, Casale V, Villotti G, Marcheggiano A, Stigliano V, Pinnaro P, Bagnardi V, Caprilli R (2000) Topical butyrate for acute radiation proctitis: randomised, crossover trial. Lancet 356:1232–1235PubMedCrossRef

Viktorin P, Putora PM, Schmid HP, Plasswilm L, Schwab C, Thoeni A, Hochreiter W, Prikler L, Suter S, Stucki P, Müntener M, Blick N, Schiefer H, Güsewell S, Zürn K, Engeler D (2020) Long-term oncological and functional follow-up in low dose rate brachytherapy (LDR-BT) for prostate cancer: results from the prospective nation-wide Swiss Registry. BJU Int [Epub ahead of print]

Vuolukka K, Auvinen P, Palmgren JE, Voutilainen T, Aaltomaa S, Kataja V (2019) Long-term efficacy and urological toxicity of low-dose-rate brachytherapy (LDR-BT) as monotherapy in localized prostate cancer. Brachytherapy [Epub ahead of print]

Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A, Souchon R, Stöckle M, Rübe C, Weissbach L, Althaus P, Rebmann U, Kälble T, Feldmann HJ, Wirth M, Hinke A, Hinkelbein W, Miller K (2009) Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 27:2924–2930PubMedCrossRef

Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL (2008) Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 148:435–448PubMedCrossRef

Wortel RC, Incrocci L, Pos FJ, Lebesque JV, Witte MG, van der Heide UA, van Herk M, Heemsbergen WD (2015) Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients. Int J Radiat Oncol Biol Phys 91:737–744PubMedCrossRef

Yavuz MN, Yavuz AA, Aydin F, Can G, Kavgaci H (2002) The efficacy of octreotide in the therapy of acute radiation-induced diarrhea: a randomized controlled study. Int J Radiat Oncol Biol Phys 54:195–202PubMedCrossRef

Yu T, Zhang Q, Zheng T, Shi H, Liu Y, Feng S, Hao M, Ye L, Wu X, Yang C (2016) The effectiveness of intensity modulated radiation therapy versus three-dimensional radiation therapy in prostate cancer: a meta-analysis of the literatures. PLoS ONE 11:e0154499PubMedPubMedCentralCrossRef

Zelefsky MJ, Aschkenasy E, Kelsen S, Leibel SA (1997) Tolerance and early outcome results of postprostatectomy three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 39:327–333PubMedCrossRef

Zelefsky MJ, Kollmeier M, Cox B, Fidaleo A, Sperling D, Pei X, Carver B, Coleman J, Lovelock M, Hunt M (2012) Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 84:125–129PubMedCrossRef

Zelefsky MJ, Shasha D, Branco RD, Kollmeier M, Baser RE, Pei X, Ennis R, Stock R, Bar-Chama N, Mulhall JP (2014) Prophylactic sildenafil citrate improves select aspects of sexual function in men treated with radiotherapy for prostate cancer. J Urol 192:868–874PubMedCrossRef

Zimmermann FB, Kummermehr J (2000) Darm und Rektum. In: Dörr W, Zimmermann JS, Seegenschmiedt MH (Hrsg) Nebenwirkungen in der Radioonkologie. Urban und Vogel, München, S 149–156

Titel: Strahlentherapie: Methodenspezifische Komplikationen
verfasst von: Dirk Bottke
Verlag: Springer Berlin Heidelberg
Buch: Komplikationen in der Urologie
Print ISBN: 978-3-662-60624-7

Electronic ISBN: 978-3-662-60625-4

Copyright-Jahr: 2021
DOI: https://doi.org/10.1007/978-3-662-60625-4_35

Neu im Fachgebiet Urologie

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

02.05.2024 DCK 2024 Kongressbericht

Die Hybrid-DRG-Verordnung soll dazu führen, dass mehr chirurgische Eingriffe ambulant durchgeführt werden, wie es in anderen Ländern schon länger üblich ist. Die gleiche Vergütung im ambulanten und stationären Sektor hatten Niedergelassene schon lange gefordert. Aber die Umsetzung bereitet ihnen doch Kopfzerbrechen.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Harninkontinenz: Netz-Op. erfordert über lange Zeit intensive Nachsorge

30.04.2024 Harninkontinenz Nachrichten

Frauen mit Belastungsinkontinenz oder Organprolaps sind nach einer Netz-Operation keineswegs beschwerdefrei. Vielmehr scheint die Krankheitslast weiterhin hoch zu sein, sogar höher als von harninkontinenten Frauen, die sich nicht haben operieren lassen.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen